| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10032762 | HBV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS10059189 | HBV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30014568 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30077154 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS30024844 | HIV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS20068134 | HPV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS44007688 | HTLV-1 | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
| TVIS43000129 | MCV | ENSG00000163399.16 | protein_coding | ATP1A1 | Yes | Yes | 476 | P05023 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ATP1A1 |
|---|---|
| DrugBank ID | DB01345 |
| Drug Name | Potassium cation |
| Target ID | BE0000732 |
| UniProt ID | P05023 |
| Regulation Type | |
| PubMed IDs | 17334838; 17347782; 17366541; 17369284; 17444965 |
| Citations | Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28.@@Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8.@@Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6.@@Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16.@@Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | [K+] |
| Pathways | Lidocaine (Antiarrhythmic) Action Pathway; Esomeprazole Action Pathway; Metolazone Action Pathway; Omeprazole Action Pathway; Nimodipine Action Pathway; Benzocaine Action Pathway; Lansoprazole Action Pathway; Famotidine Action Pathway; Alprenolol Action Pathway; Procainamide (Antiarrhythmic) Action Pathway; Pantoprazole Action Pathway; Pirenzepine Action Pathway; Rabeprazole Action Pathway; Glycolysis; Hartnup Disorder; Xanthine Dehydrogenase Deficiency (Xanthinuria); Adenylosuccinate Lyase Deficiency; S-Adenosylhomocysteine (SAH) Hydrolase Deficiency; Torsemide Action Pathway; Ranitidine Action Pathway; Hydrochlorothiazide Action Pathway; Glycine N-Methyltransferase Deficiency; Hypermethioninemia; Triamterene Action Pathway; Lysinuric Protein Intolerance; Glucose Transporter Defect (SGLT2); Methyclothiazide Action Pathway; Methylenetetrahydrofolate Reductase Deficiency (MTHFRD); Nisoldipine Action Pathway; Furosemide Action Pathway |
| PharmGKB | PA451047 |
| ChEMBL |
